Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash-to-Debt 0.16
MNKD's Cash-to-Debt is ranked lower than
94% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. MNKD: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
MNKD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.33 Max: No Debt
Current: 0.16
Equity-to-Asset -2.48
MNKD's Equity-to-Asset is ranked lower than
98% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. MNKD: -2.48 )
Ranked among companies with meaningful Equity-to-Asset only.
MNKD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.48  Med: -0.58 Max: 0.87
Current: -2.48
-2.48
0.87
Piotroski F-Score: 3
Altman Z-Score: -45.64
Beneish M-Score: 4127.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -119.35
MNKD's Operating Margin % is ranked lower than
60% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. MNKD: -119.35 )
Ranked among companies with meaningful Operating Margin % only.
MNKD' s Operating Margin % Range Over the Past 10 Years
Min: -3073570  Med: -350481.86 Max: -119.35
Current: -119.35
-3073570
-119.35
Net Margin % -126.47
MNKD's Net Margin % is ranked lower than
61% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. MNKD: -126.47 )
Ranked among companies with meaningful Net Margin % only.
MNKD' s Net Margin % Range Over the Past 10 Years
Min: -2931900  Med: -402755.43 Max: -126.47
Current: -126.47
-2931900
-126.47
ROA % -140.01
MNKD's ROA % is ranked lower than
89% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. MNKD: -140.01 )
Ranked among companies with meaningful ROA % only.
MNKD' s ROA % Range Over the Past 10 Years
Min: -141.48  Med: -70.42 Max: -54.14
Current: -140.01
-141.48
-54.14
ROC (Joel Greenblatt) % -243.87
MNKD's ROC (Joel Greenblatt) % is ranked lower than
51% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. MNKD: -243.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNKD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -285.89  Med: -96.5 Max: -70.3
Current: -243.87
-285.89
-70.3
3-Year EBITDA Growth Rate 3.30
MNKD's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. MNKD: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNKD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43  Med: -25.4 Max: 10.9
Current: 3.3
-43
10.9
3-Year EPS without NRI Growth Rate -1.10
MNKD's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MNKD: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNKD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.9  Med: -22.9 Max: 7.6
Current: -1.1
-42.9
7.6
GuruFocus has detected 4 Warning Signs with MannKind Corp $MNKD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MNKD Guru Trades in Q1 2016

Murray Stahl Sold Out
Paul Tudor Jones 103,372 sh (-52.88%)
» More
Q2 2016

MNKD Guru Trades in Q2 2016

Paul Tudor Jones 103,325 sh (-0.05%)
» More
Q3 2016

MNKD Guru Trades in Q3 2016

Paul Tudor Jones 103,325 sh (unchged)
» More
Q4 2016

MNKD Guru Trades in Q4 2016

Joel Greenblatt 90,068 sh (New)
Paul Tudor Jones 103,325 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:IDRA, OTCPK:ELVAF, OTCPK:MXDHF, OTCPK:CLVLF, NAS:IMGN, NAS:AVXL, NAS:SRNE, NAS:KMDA, OTCPK:THERF, NAS:CGEN, OTCPK:RCAR, NAS:MNOV, NAS:ABEO, NAS:SGMO, NAS:CYAD, OTCPK:SPHRY, OTCPK:SPRWF, OTCPK:VNLPY, OTCPK:OXBDF, NAS:CCXI » details
Traded in other countries:NNF1.Germany,
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.

MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.

Ratios

vs
industry
vs
history
PS Ratio 1.58
MNKD's PS Ratio is ranked higher than
88% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. MNKD: 1.58 )
Ranked among companies with meaningful PS Ratio only.
MNKD' s PS Ratio Range Over the Past 10 Years
Min: 1.28  Med: 3930 Max: 10655
Current: 1.58
1.28
10655
Current Ratio 0.46
MNKD's Current Ratio is ranked lower than
92% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. MNKD: 0.46 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.32 Max: 12.24
Current: 0.46
0.12
12.24
Quick Ratio 0.41
MNKD's Quick Ratio is ranked lower than
91% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. MNKD: 0.41 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.32 Max: 12.24
Current: 0.41
0.12
12.24
Days Inventory 201.28
MNKD's Days Inventory is ranked lower than
72% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. MNKD: 201.28 )
Ranked among companies with meaningful Days Inventory only.
MNKD' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 201.28
Current: 201.28
0
201.28
Days Sales Outstanding 7.05
MNKD's Days Sales Outstanding is ranked higher than
89% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. MNKD: 7.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNKD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.05  Med: 8825.7 Max: 30331.5
Current: 7.05
7.05
30331.5
Days Payable 163.28
MNKD's Days Payable is ranked higher than
81% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. MNKD: 163.28 )
Ranked among companies with meaningful Days Payable only.
MNKD' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 163.28
Current: 163.28
0
163.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.40
MNKD's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. MNKD: -14.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -42.5 Max: -8
Current: -14.4
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -42.93
MNKD's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. MNKD: -42.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNKD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -43.9  Med: 157.5 Max: 7504.7
Current: -42.93
-43.9
7504.7

More Statistics

Revenue (TTM) (Mil) $162.4
EPS (TTM) $ -0.55
Beta3.25
Short Percentage of Float28.07%
52-Week Range $0.41 - 2.24
Shares Outstanding (Mil)478.64

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) 0.11 -0.09 -0.10 -0.06
EPS without NRI ($) 0.11 -0.09 -0.10 -0.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
Short Sellers Hike Their Bets in Major Biotechs Feb 28 2017
The 6 Most Shorted Nasdaq Stocks Feb 28 2017
Can MannKind Be Saved? Feb 27 2017
MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets Feb 23 2017
MannKind Receives $16.7 Million From Sale of Valencia Property Feb 21 2017
The 6 Most Shorted Nasdaq Stocks Feb 10 2017
MannKind Looks to Boost Flagging Afrezza Sales Feb 02 2017
Mannkind in Free Fall After Changes to Insulin Product, Sales Force Feb 02 2017
Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on... Feb 01 2017
MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza®... Feb 01 2017
MannKind Corporation to Hold Investor Conference Call on February 1, 2017 Jan 27 2017
Short Sellers Back Off Major Biotechs Jan 26 2017
The 6 Most Shorted Nasdaq Stocks Jan 26 2017
Insulin Drug Offers Hope for MannKind Jan 12 2017
Biotech Short Sellers Run for Cover Jan 12 2017
MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)